Emmaus Life Sciences Depreciation & Amortization Growth & History (EMMA)
Emmaus Life Sciences's depreciation and amortization was $39,000 for fiscal 2025.
View full Emmaus Life Sciences company overviewEmmaus Life Sciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $39,000 | $17,000 | +77.27% |
| 2024 | 2024-12-31 | $22,000 | −$10,000 | −31.25% |
| 2023 | 2023-12-31 | $32,000 | −$21,000 | −39.62% |
| 2022 | 2022-12-31 | $53,000 | −$6,000 | −10.17% |
| 2021 | 2021-12-31 | $59,000 | −$1,000 | −1.67% |
| 2020 | 2020-12-31 | $60,000 | −$13,000 | −17.81% |
| 2019 | 2019-12-31 | $73,000 | $12,000 | +19.67% |
| 2018 · Dec 31 | 2018-12-31 | $61,000 | — | — |
| 2018 · Sep 30 | 2018-09-30 | $117,900 | $69,200 | +142.09% |
| 2017 | 2017-09-30 | $48,700 | $41,500 | +576.39% |
| 2016 | 2016-09-30 | $7,200 | −$400 | −5.26% |
| 2015 | 2015-09-30 | $7,600 | −$2,700 | −26.21% |
| 2014 | 2014-09-30 | $10,300 | −$2,700 | −20.77% |
| 2013 | 2013-09-30 | $13,000 | −$5,800 | −30.85% |
| 2012 | 2012-09-30 | $18,800 | — | — |
Emmaus Life Sciences quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14,000 | $10,000 | +250.00% |
| Q1 2026 | 2026-03-31 | $15,000 | $10,000 | +200.00% |
| Q4 2025 | 2025-12-31 | $15,000 | — | — |
| Q3 2025 | 2025-09-30 | $15,000 | $10,000 | +200.00% |
| Q2 2025 | 2025-06-30 | $4,000 | −$2,000 | −33.33% |
| Q1 2025 | 2025-03-31 | $5,000 | −$1,000 | −16.67% |
| Q3 2024 | 2024-09-30 | $5,000 | −$3,000 | −37.50% |
| Q2 2024 | 2024-06-30 | $6,000 | −$3,000 | −33.33% |
| Q1 2024 | 2024-03-31 | $6,000 | −$3,000 | −33.33% |
| Q3 2023 | 2023-09-30 | $8,000 | −$4,000 | −33.33% |
| Q2 2023 | 2023-06-30 | $9,000 | −$4,000 | −30.77% |
| Q1 2023 | 2023-03-31 | $9,000 | −$6,000 | −40.00% |
| Q3 2022 | 2022-09-30 | $12,000 | −$2,000 | −14.29% |
| Q2 2022 | 2022-06-30 | $13,000 | −$2,000 | −13.33% |
| Q1 2022 | 2022-03-31 | $15,000 | $0 | 0.00% |
| Q3 2021 | 2021-09-30 | $14,000 | −$1,000 | −6.67% |
| Q2 2021 | 2021-06-30 | $15,000 | $0 | 0.00% |
| Q1 2021 | 2021-03-31 | $15,000 | $0 | 0.00% |
| Q3 2020 | 2020-09-30 | $15,000 | −$4,000 | −21.05% |
| Q2 2020 | 2020-06-30 | $15,000 | −$3,000 | −16.67% |
| Q1 2020 | 2020-03-31 | $15,000 | −$2,000 | −11.76% |
| Q3 2019 | 2019-09-30 | $19,000 | $6,000 | +46.15% |
| Q2 2019 | 2019-06-30 | $18,000 | −$12,200 | −40.40% |
| Q1 2019 | 2019-03-31 | $17,000 | −$17,200 | −50.29% |
| Q4 2018 · Dec 31 | 2018-12-31 | $30,200 | $6,900 | +29.61% |
| Q4 2018 | 2018-09-30 | $13,000 | — | — |
| Q3 2018 | 2018-06-30 | $30,200 | $15,200 | +101.33% |
| Q2 2018 | 2018-03-31 | $34,200 | $24,100 | +238.61% |
| Q1 2018 | 2017-12-31 | $23,300 | $15,300 | +191.25% |
| Q3 2017 | 2017-06-30 | $15,000 | $13,800 | +1150.00% |
| Q2 2017 | 2017-03-31 | $10,100 | $8,800 | +676.92% |
| Q1 2017 | 2016-12-31 | $8,000 | $6,600 | +471.43% |
| Q3 2016 | 2016-06-30 | $1,200 | −$400 | −25.00% |
| Q2 2016 | 2016-03-31 | $1,300 | −$900 | −40.91% |
| Q1 2016 | 2015-12-31 | $1,400 | −$800 | −36.36% |
| Q3 2015 | 2015-06-30 | $1,600 | −$800 | −33.33% |
| Q2 2015 | 2015-03-31 | $2,200 | −$400 | −15.38% |
| Q1 2015 | 2014-12-31 | $2,200 | −$600 | −21.43% |
| Q3 2014 | 2014-06-30 | $2,400 | −$1,700 | −41.46% |
| Q2 2014 | 2014-03-31 | $2,600 | $600 | +30.00% |
| Q1 2014 | 2013-12-31 | $2,800 | −$1,200 | −30.00% |
| Q3 2013 | 2013-06-30 | $4,100 | −$200 | −4.65% |
| Q2 2013 | 2013-03-31 | $2,000 | −$2,400 | −54.55% |
| Q1 2013 | 2012-12-31 | $4,000 | $0 | 0.00% |
| Q3 2012 | 2012-06-30 | $4,300 | — | — |
| Q2 2012 | 2012-03-31 | $4,400 | — | — |
| Q1 2012 | 2011-12-31 | $4,000 | — | — |
Emmaus Life Sciences depreciation and amortization trends
Over the last five fiscal years, Emmaus Life Sciences's depreciation and amortization decreased from $60,000 to $39,000, a change of −$21,000. The latest reported quarter, Q2 2026, shows $14,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emmaus Life Sciences source filings ↗